Simplifying and adapting antiretroviral treatment in resource-poor settings: A necessary step to scaling-up

AIDS

Volumn 18, Issue 18, 2004, Pages 2353-2360

  Calmy, Alexandra ^a   Klement, Elise ^a   Teck, Roger ^a   Berman, Daniel ^a   Pécoul, Bernard ^a   Ferradini, Laurent ^b   Ford, Nathan ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b EPICENTRE   (France)

Author keywords

Antiretroviral treatment; Resource poor setting; Scaling up; Simplification

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIBIOTIC RESISTANCE; CENTRALIZATION; COST OF ILLNESS; DEVELOPING COUNTRY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MARKETING; DRUG SUBSTITUTION; DRUG TOLERABILITY; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER TOXICITY; MEDICAL DECISION MAKING; MEDICAL ETHICS; NEUROTOXICITY; PRIORITY JOURNAL; RASH; RESOURCE ALLOCATION; REVIEW; RISK FACTOR; SCALE UP; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CLINICAL PROTOCOLS; COMMUNICABLE DISEASE CONTROL; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HEALTH CARE RATIONING; HIV INFECTIONS; HUMANS; MALE;

EID: 11244263183     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. World Health Organization. Treating 3 million by 2005: Making it happen. The WHO Strategy. Geneva: World Health Organization; 2003. Available at http://www.who.int/3by5/publications/documents/en/3by5StrategyMakingItHappen. pdf.
2. UNAIDS. AIDS Epidemic Update. Geneva: UNAIDS; 2003.
3. Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3 year follow up study. Antivir Ther 2003, 8:585-594.
4. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2004.
5. Médecins sans Frontière Campaign for Access to Essential Medicines. ARV Simplification for High-Prevalence Countries. Nairobi, September, 2003. Available at http://www.accessmed-msf.org/prod/publications.asp?scntid= 1312004953434&contenttype =PARA&.
6. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003, 17:2451-2459.
7. Kumar S. Indian company offers to supply AIDS drugs at low cost. Lancet 2001, 257:616.
8. Kober K, van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet 2004, 364:103-107.
9. Kuhse H, Singer P (eds.). Bioethics: An Anthology. Oxford: Blackwell; 1999.
10. Calmy A, Pinoges L, Cirera A, Humblet P, Pascual F, Szumilin E, et al. Increased access to HAART in resource-poor settings in Médecins sans Frontières programmes: outcomes of adults at 18 months of treatment. XV International Conference on AIDS. Bangkok, July, 2004 [abstract ThPeB7179].
11. Centers for Disease Control and Prevention. The Adult and Adolescent Guidelines for Antiretroviral Treatment. http://aidsinfo.nih.gov/guidelines/ default_db2.asp?id=50.
12. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization, 2004. Available at http://www.who.int/3by5/ publications/guidelines/en/execsumm.pdf.
13. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004, 364:29-34.
14. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
15. Médecins sans Frontières. Briefing Note on Fixed-dose Combinations (FDCs) of Antiretroviral Drugs. Geneva: Médecins sans Frontières; 2004. Available at: http://www.accessmed-msf.org/documents/ factsheetfdc.pdf.
16. World Health Organization. Prequalifying Priority Medicines. Ensuring the Quality, Safety and Efficacy of HIV/AIDS, Tuberculosis and Malaria Medicines and Diagnostics. Geneva: World Health Organization, 2004.
17. Ferradini L, Macé C, Pinoges L, Cirera A, Pascual F, Humblet P, et al. Very satisfactory outcomes of fixed dose combinations (FDCs) of anti-retroviral drugs among patients on HAART in Médecins sans Frontières programmes. XV International Conference on AIDS. Bangkok, July, 2004 [abstract Weor 1317].
18. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004, 350:1850-1861.
19. Calmy A. Pascual F, Ford N. First-line and second-line antiretroviral therapy. Lancet 2004, 364:329.
20. Médecins sans Frontières. Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries, 6th edn. Geneva: Médecins sans Frontières; 2004. Available at: http://www.accessmed-msf.org/prod/publications. asp?scntid= 22420041625454&contenttype=PARA&.
21. Anon. Children Missing Out on HIV Drugs. London: UK BBC, 14 July 2004. Available at: http://news.bbc.co.uk/2/hi/health/3892583.stm.
22. Fryland M, Chaillet P, Bonte L, Barnaba A, Teck R, Odiambo D, et al. The PARTEC CyFlow counter for CD4+ T-cell counting produces high quality results and is robust when evaluated under routine field conditions in Malawi. XV International Conference on AIDS. Bangkok, July, 2004 [abstract TuOrB1149].
23. Perkins MD. New diagnostic tools for tuberculosis. Int J Tuberc Lund Dis 2000, 4:S182-S188.
24. Havlir DV, Barnes PF. Tuberculosis in patients with HIV infection. New Engl J Med 1999 340:367-373.
25. Elliott AM, Halwiindi B, Haves RJ, Luo N, Tembo G, Machiels L et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993, 96:1-11.
26. Harries AD, Nayngulu DS, Banda H, Kang'ombe C, van der Paal L, Glynn JR, et al. Efficacy of an unsupervised ambulatory treatment regimen for smear negative pulmonary tuberculosis and tuberculosis pleural effusion in Malawi. Int J Tuberc Lung Dis 1999, 3:402-408.
27. van Oosterhout JJG, Bodasing N, Nyirenda C, Kumwenda JJ, Mallewa J, Zijlstra EE. Evaluation of the antiretoviral treatment programme at Queen Elizabeth Hospital (QECH), Blantyre, Malawi. XV International Conference on AIDS. Bangkok, July, 2004 [abstract ThPeB7199].
28. Nelson R. USA urged to accept generic AIDS drugs. Lancet 2004, 363:1205.
29. World Health Organization. Antiretroviral Therapy in Primary Health Care: Experience of the Chiradzulu Programme in Malawi. World Health Organization Case Study. Geneva: World Health Organization; in press.
30. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18:887-895.
31. Kumphitak A, Kasi-Sedapan S, Wilson D, Ford N, Adpoon P, Kaetkaew S, et al. Perspectives and Practice in Antiretroviral Treatment: Involvement of people living with HIV/AIDS in Treatment Preparedness. Geneva: World Health Organization and MSF/TNP+/AAF; 2004.
32. Anon. Africa: Simplified, High-Quality Public Health Initiatives Needed. Bangkok: UN Integrated Regional Information Network; 2004.
33. Pérez-Casas C. Setting Price Objectives: Is There A Political Will? Geneva: Médecins sans Frontières; 2000.
34. Ahmad K. Clinton pledges cheap antiretrovirals. Lancet Infect Dis 2003, 3:745.
35. Laniece J, Diop K, Desclaux A, Sow K, Ciss M, Ndiaye B, et al. Determinants of long-term adherence to antiretroviral drugs among adults followed over four years in Dakar, Senegal. XV International Conference on AIDS. Bangkok, July, 2004 [abstract WeOrB1320].
36. 't Hoen E. TRIPS, pharmaceutical patents and access to essential medicines: a long way from Seattle to Doha. Chic J Int Law 2002, 3:27-48.
37. Folkers GK, Fauci AS. The AIDS research model: implications for other infectious diseases of global health importance. JAMA 2001, 286:458-461.
38. Ford N, Torreele E. Neglected diseases of global importance. JAMA 2001, 286:2943.
39. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002 359:2188-2194.
40. Anon. Global Aids Fund Facing Serious Cash Crunch. Reuters, 10 March, 2004.
41. Anon. Lack of Funds hits World Health Organization Anti-AIDS Project. Financial Times, 18 March, 2004.